Literature DB >> 16108944

Agreement between patient and proxy responses of health-related quality of life after hip fracture.

C Allyson Jones1, David H Feeny.   

Abstract

OBJECTIVES: To examine agreement between patient and proxy respondents on health-related quality of life (HRQL) over time during the 6-month recovery after hip fracture.
DESIGN: Prospective longitudinal cohort study.
SETTING: A healthcare region serving Edmonton, Alberta, and the surrounding area. PARTICIPANTS: Two hundred forty-five patients aged 65 and older, were treated for hip fracture, and had Mini-Mental State Examination scores greater than 17; 245 family caregivers participated as proxy respondents. MEASUREMENTS: Primary outcome was HRQL (Health Utilities Mark 2 and Mark 3). Interviews were completed within 5 days after surgery and at 1, 3, and 6 months. Agreement was evaluated using intraclass correlation coefficients (ICCs).
RESULTS: Agreement was considered moderate to excellent for HRQL. ICC values ranged from 0.50 to 0.85 (P<.001) for physically based observable dimensions of health status and from 0.32 to 0.66 (P<.01) for less-observable dimensions. Agreement improved with time. Time and the number of days between patient and proxy interviews were significant factors in accounting for patient-proxy differences.
CONCLUSION: Although proxy and patient responses are not interchangeable, proxy responses provide an option for assessing function and health status in patients who are unable to respond on their own behalf.

Entities:  

Mesh:

Year:  2005        PMID: 16108944     DOI: 10.1111/j.1532-5415.2005.53374.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  8 in total

1.  Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients.

Authors:  David Feeny; Karen Spritzer; Ron D Hays; Honghu Liu; Theodore G Ganiats; Robert M Kaplan; Mari Palta; Dennis G Fryback
Journal:  Med Decis Making       Date:  2011-10-18       Impact factor: 2.583

2.  Health status in patients with Alzheimer's disease: an investigation of inter-rater agreement.

Authors:  J L Novella; F Boyer; C Jochum; N Jovenin; I Morrone; D Jolly; S Bakchine; F Blanchard
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 4.147

3.  Longitudinal construct validity of the Health Utilities Indices Mark 2 and Mark 3 in hip fracture.

Authors:  C Allyson Jones; Sheri L Pohar; David H Feeny; Ken Eng
Journal:  Qual Life Res       Date:  2013-10-01       Impact factor: 4.147

4.  Proxy and patients ratings on quality of life in patients with schizophrenia and bipolar disorder in Korea.

Authors:  Eun Joo Kim; Dong Ho Song; Se Joo Kim; Jin Young Park; Eun Lee; Jeong Ho Seok; Duk-In Jon; Hyun-Sang Cho
Journal:  Qual Life Res       Date:  2010-03-04       Impact factor: 4.147

Review 5.  Patient-reported outcome measures in older people with hip fracture: a systematic review of quality and acceptability.

Authors:  K L Haywood; J Brett; E Tutton; S Staniszewska
Journal:  Qual Life Res       Date:  2016-10-20       Impact factor: 4.147

6.  Can Proxy Ratings Supplement Patient Report to Assess Functional Domains Among Hospitalized Patients?

Authors:  David J Weiss; Chun Wang; King Yiu Suen; Jeffrey Basford; Andrea Cheville
Journal:  Arch Phys Med Rehabil       Date:  2021-10-20       Impact factor: 4.060

7.  Psychometric properties of health-related quality of life instruments in patients undergoing palmar fasciectomy for dupuytren's disease: a prospective study.

Authors:  Achilleas Thoma; Manraj Nirmal Kaur; Teegan Aili Ignacy; Carolyn Levis; Stuart Martin; Eric Duku; Ted Haines
Journal:  Hand (N Y)       Date:  2014-06

8.  Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.

Authors:  Femke A H van der Linden; Jolijn J Kragt; Margarethe van Bon; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard M J Uitdehaag
Journal:  BMC Neurol       Date:  2008-02-28       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.